Weve done the homework so you dont have to
Last quarter, the company submitted its drug orforglipron, a new GLP-1 agonist, for obesity treatment in the United States and more than three dozen additional countries, with an expected domestic launch by mid-2026
Curcumin not only has powerful antioxidant activity, but it has also been shown to induce the biosynthesis of glutathione within cells
Interactomes of SARS-CoV-2 and human coronaviruses reveal host factors potentially affecting pathogenesis
Thus, the observed c-Fos activation pattern elicited by semaglutide in this study is consistent with a brainstem-to-amygdala circuit engaged in appetite-regulating pathways
Phase 2 Clinical Trial Data The landmark Phase 2 trial of retatrutide in obesity was a 48-week, randomized, double-blind, placebo-controlled study published in The New England Journal of Medicine in 2023